Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
inbx · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 5 Wall Street analysts in the past 3 months
Buy
5 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$325
Consensus
$325
+264.6% upside
Low
$325
Median: $325 · Last Close: $89.13
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $84.67 | ↓ 5.00% |
1-day model range: $83.79–$85.56. Peak: $85.56 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · INBX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-22 | JMP Securities | Maintains | Market Perform→Market Perform |
| 2025-05-15 | JMP Securities | Maintains | Market Perform→Market Perform |
| 2025-03-18 | Citizens Capital Markets | Maintains | Market Perform→Market Perform |
| 2025-01-22 | JMP Securities | Maintains | Market Perform→Market Perform |
| 2024-01-23 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2023-11-20 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-08-23 | JMP Securities | Maintains | Outperform→Outperform |
| 2023-05-10 | JMP Securities | Maintains | Market Outperform→Outperform |
| 2023-03-08 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-03-07 | Credit Suisse | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Inhibrx Biosciences, Inc. (INBX) stock. Of the recent 19 rating actions, 0 were upgrades and 1 were downgrades. 5 analysts currently cover INBX.
Analyst Recommendation Trends
INBX analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4M
↓ 96.7% YoY
Revenue Next Year
$57M
↑ 1230.2% YoY
EPS This Year
$-9.23
EPS Next Year
$-6.53
↓ 29.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast INBX EPS of $-9.23 for the current fiscal year, based on estimates from 1 analysts. The INBX revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The INBX stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus INBX price target is $325.00 (+264.6% upside), with an analyst consensus of Buy.
The INBX short-term stock prediction for tomorrow is $84.67 (-5.00%).
Inhibrx Biosciences, Inc. trades on NASDAQ under the ticker INBX. The INBX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 60% of covering analysts.
Frequently asked questions
INBX forecast · 8 questionsAccording to 5 Wall Street analysts, the average 12-month INBX price target is $325.00, with a high forecast of $325.00 and a low of $325.00. The median price target is shown in the chart above when available. This implies +264.6% potential upside from the current price of $89.13.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.